Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome

Beckers, Rhiannon K, Selinger, Christina I, Vilain, Ricardo, Madore, Jason, Wilmott, James S, Harvey, Kate, Holliday, Anne, Cooper, Caroline L, Robbins, Elizabeth, Gillett, David, Kennedy, Catherine W, Gluch, Laurence, Carmalt, Hugh, Mak, Cindy, Warrier, Sanjay, Gee, Harriet E, Chan, Charles, McLean, Anna, Walker, Emily, McNeil, Catriona M, Beith, Jane M, Swarbrick, Alexander, Scolyer, Richard A, O'Toole, Sandra A·2016·Histopathology

Abstract

Aims: Triple‐negative breast cancer (TNBC) patients generally have a poor outcome; there is a pressing need to identify more effective therapeutic strategies. Clinical trials targeting programmed death 1/programmed death ligand 1 (PD 1/PDL 1) in melanoma and non‐small‐cell lung cancer have reported high response rates, and tumoral PDL 1 expression has been suggested as a potential biomarker to enrich for patient response to these treatments. There are only very limited data to date reporting the expression of PDL 1 in TNBC. Methods and results: PDL 1 immunohistochemistry was performed on 161 primary TNBC s and assessed in the tumour as well as immune cells in the stromal compartment. PDL 1 expression was very common in TNBC, expressed in the tumour cell membrane (64%), cytoplasm (80%) and stromal (93%) cellular compartments. Cytoplasmic tumoral expression of PDL 1 was associated with a lower risk of breast cancer‐specific death [hazard ratio (HR) 0.45, P = 0.035] while stromal PDL 1 expression was associated with a lower rate of deaths from all causes (HR 0.305, P = 0.0042). Membranous expression of PDL 1 was not associated with outcome. While both PDL 1 expression and tumour‐infiltrating lymphocytes were associated with a better outcome, only lymphovascular invasion and high tumour‐infiltrating lymphocytes were independently prognostic for breast cancer‐specific death. Conclusion: While PDL 1 expression is frequent in TNBC, it was not independently prognostic. There were differences in outcome depending on the cellular compartment of PDL 1 expression. These data provide further impetus for investigating the utility of immune checkpoint therapies in TNBC, given the clinical significance of tumour‐infiltrating lymphocytes (TIL s) and PDL 1 expression in this cohort.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/his.12904

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 231

Metadata

Authors
Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., Kennedy, C. W., Gluch, L., Carmalt, H., Mak, C., Warrier, S., Gee, H. E., Chan, C., McLean, A., Walker, E., McNeil, C. M., Beith, J. M., Swarbrick, A., Scolyer, R. A., & O'Toole, S. A.
Venue
Histopathology
Publisher
Wiley
Published
2016-01-13
Volume
69
Issue
1
Pages
25-34
ISSN
  • 0309-0167 (ISSN-L)
  • 1365-2559
OpenAlex
W2277555391
Cited by
231
References
3
FWCI
6.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.